International Journal of Biological Sciences (ISSN: 1449-2288, E-ISSN: 1449-2288) is a premier open-access journal published by IVYSPRING INTERNATIONAL PUBLISHING since 2005, located in Australia. With a commitment to advancing knowledge in the life sciences, this journal covers a wide spectrum of disciplines, including Applied Microbiology and Biotechnology, Cell Biology, Developmental Biology, Ecology, Evolution, Behavior and Systematics, and Molecular Biology, earning a distinguished Q1 ranking in these fields as of 2023. It stands out with exceptional Scopus rankings, placing in the top ranks across multiple categories, such as the 98th percentile in Ecology, Evolution, Behavior and Systematics and the 94th percentile in Applied Microbiology and Biotechnology. The journal fosters an open access philosophy, ensuring that research findings are readily available to the scientific community and the public, and invites original research articles, reviews, and commentaries. With its mission to disseminate high-quality research, the International Journal of Biological Sciences serves as an essential resource for researchers, professionals, and students seeking to deepen their understanding and drive innovation in biological sciences.

CYTOTECHNOLOGY, an esteemed journal published by Springer, stands as a vital resource in the fields of Bioengineering, Biomedical Engineering, and Biotechnology. With an impact factor reflective of its solid position within academia, this journal encompasses a broad scope dedicated to the advancement of cytotechnological research and applications from its inception in 1987 through to its latest volumes in 2024. Based in the Netherlands, it is committed to providing researchers, professionals, and students with high-quality, peer-reviewed articles that contribute to the understanding and innovations in cytotechnology. Although currently not open access, CYTOTECHNOLOGY has garnered a commendable reputation, holding Q3 rankings in multiple categories, indicating its relevance and influence within the scientific community. Researchers are encouraged to submit their cutting-edge findings to share insights that can spark further advancements in this dynamic field.

Molecular Medicine Reports, an esteemed academic journal published by Spandidos Publications Ltd, serves as a vital platform for the dissemination of cutting-edge research in the field of molecular medicine. Established in 2008, this journal has rapidly ascended in prominence, currently positioned within the Q2 and Q3 quartiles across various critical categories including Biochemistry, Cancer Research, and Genetics, reflecting its significant impact and scholarly contributions. With an impressive Scopus ranking in multiple disciplines, including an 87th place in Oncology, it is recognized for publishing rigorous, peer-reviewed articles that bridge the gap between laboratory research and clinical applications. The journal’s commitment to advancing knowledge in molecular medicine is evident through its focus on innovative therapeutic approaches, genetic research, and oncological studies, catering to a diverse readership of researchers, professionals, and students in the biomedical field. Though not an open-access publication, it provides invaluable insights and fosters collaboration in the scientific community from its base in Athens, Greece.

CELL BIOLOGY AND TOXICOLOGY, published by SPRINGER, stands as a vital journal within the realms of cell biology and toxicology, boasting an impressive 2023 Q1 ranking in its fields, alongside robust Scopus rankings placing it in the top 11th percentile for Toxicology and the 22nd for Health, Toxicology and Mutagenesis. With an ISSN of 0742-2091 and an E-ISSN of 1573-6822, the journal has been a cornerstone of scientific discourse since its inception in 1984, and will continue to converge innovative research until 2024. The journal focuses on the interplay between cellular mechanisms and toxicological implications, making it an essential resource for researchers, healthcare professionals, and students keen on advancing their understanding of these critical areas. Although it does not offer open access, its high impact and prestigious standing ensure that its publications reach a wide audience dedicated to significant advancements in the life sciences.

The Journal of Gene Medicine, published by Wiley, stands as a pivotal resource in the field of gene therapy and molecular medicine, with a rich history of dissemination of impactful research since its inception in 1998. With an ISSN of 1099-498X and an E-ISSN of 1521-2254, this esteemed journal plays a crucial role in advancing our understanding of genetics and drug discovery, reflected in its impressive 2023 Scopus rankings where it holds a Q2 classification in Drug Discovery and Q3 in several genetics-related categories. The journal aims to facilitate the exchange of high-quality research findings that bridge the gap between laboratory and clinical applications, making it an essential platform for researchers, academics, and healthcare professionals committed to the forefront of genetic innovation. Although it does not currently offer open access options, its reputation for rigorous peer review ensures that all published work meets the highest academic standards, providing a reliable reference for scientific inquiry in the United States and beyond. As the field rapidly evolves, the Journal of Gene Medicine remains at the helm, guiding future discoveries with its influential publications and comprehensive insights.

MOLECULAR AND CELLULAR BIOLOGY, published by TAYLOR & FRANCIS INC, stands as a preeminent platform for researchers, professionals, and students engaged in the dynamic field of molecular and cellular biology. Established in 1981 and ongoing into 2024, the journal features cutting-edge research that spans across vital sub-disciplines, garnering a strong impact in its contributions to the scientific community. With an impressive Q2 ranking in Cell Biology and Q1 ranking in Molecular Biology for 2023, it consistently publishes high-quality articles that reflect the latest advancements and discoveries within the field. The journal is particularly well-regarded for its rigorous peer-review process and commitment to scientific excellence, making it an invaluable resource for those seeking to deepen their understanding of molecular mechanisms and cellular processes. Although not open access, the journal offers diverse access options for researchers to reach the latest findings. By maintaining a strong focus on biochemistry, genetics, and molecular biology, MOLECULAR AND CELLULAR BIOLOGY remains essential reading for anyone looking to contribute to or stay informed about significant developments within this pivotal area of study.

CELL CYCLE, an esteemed journal published by Taylor & Francis Inc., stands at the forefront of biological research, focusing on the intricate mechanisms of cell proliferation, molecular biology, and developmental biology. With an ISSN of 1538-4101 and an E-ISSN of 1551-4005, this journal has established its influence in the field with a commendable impact factor reflecting its rigorous peer-review process and high-quality publications. Notably, in 2023, it achieved a Q1 ranking in Medicine (miscellaneous) and a Q2 ranking in both Cell Biology and Developmental Biology, marking its vital role in advancing scientific understanding and innovation. Operating within a converged framework from 2002 to 2024, CELL CYCLE caters to a diverse audience of researchers, professionals, and students eager to explore contemporary findings and emerging trends. The journal's objective is to disseminate groundbreaking research that enhances our understanding of cellular mechanisms, fostering collaboration and innovation. Although not an open-access journal, it remains a premier source for those engaged in cell cycle research, and its contributions have significant implications for fields such as healthcare, biotechnology, and genetics.

BIOFACTORS, an esteemed journal published by Wiley, serves as a pivotal resource in the fields of Biochemistry, Clinical Biochemistry, and Molecular Medicine. With ISSN 0951-6433 and E-ISSN 1872-8081, the journal has established its reputation since its inception in 1988, showcasing a rich history of scientific inquiry and innovation. Recognized for its high academic standards, it currently holds a Q1 ranking in key categories, including Biochemistry and Medicine (miscellaneous), and ranks in the top 10% for Clinical Biochemistry according to Scopus metrics, reflecting its impact and influence in the scientific community. Although it does not offer Open Access, BIOFACTORS provides researchers the opportunity to publish and disseminate high-quality studies that advance our understanding of biological factors and their clinical implications. The journal actively encourages contributions that bridge the gap between laboratory findings and clinical applications, making it a vital platform for both seasoned researchers and emerging scholars in the life sciences.

The International Journal of Biochemistry & Cell Biology, published by Pergamon-Elsevier Science Ltd, stands as a pivotal resource in the fields of biochemistry and cell biology. With an ISSN of 1357-2725 and an E-ISSN of 1878-5875, this prestigious journal has been a key platform for disseminating cutting-edge research since its inception in 1995. The journal currently holds an impressive Q1 ranking in Biochemistry and a Q2 ranking in Cell Biology for the year 2023, reflecting its commitment to high-quality research and its influence within the scientific community. With a significant Scopus ranking of 94/438 in Biochemistry and 96/285 in Cell Biology, the journal plays a crucial role in advancing knowledge and fostering innovative approaches in these dynamic fields. Though it is not an open-access journal, the International Journal of Biochemistry & Cell Biology remains accessible to a wide audience, making it a vital resource for researchers, professionals, and students alike, who are eager to explore and contribute to the ongoing advancements in biochemistry and cell biology.

Molecular Cancer, published by BMC, stands as a premier open access journal dedicated to advancing our understanding of cancer biology, treatment, and prevention since its inception in 2002. With an impressive Q1 ranking in the domains of Cancer Research, Molecular Medicine, and Oncology, this journal occupies a significant position in the academic landscape, emphasizing high-quality research that influences clinical practices and future studies. The journal is indexed in leading databases with exceptional Scopus ranks, reflecting its rigorous peer-review process and impactful contributions to the field, where it ranks in the top 2-3 positions across various relevant categories. Based in the United Kingdom, Molecular Cancer offers researchers worldwide a valuable platform for disseminating innovative findings that drive the biomedical community forward. The journal's open access model ensures that groundbreaking research is freely accessible, fostering collaboration and knowledge sharing among professionals, students, and academics alike. Explore cutting-edge developments in cancer research through Molecular Cancer and join a community committed to improving patient outcomes and advancing scientific discovery.